 | • レポートコード：B-MOR-040813 • 出版社/出版日：Mordor Intelligence / 2018年2月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、遺伝子検査（MD）の世界市場について調べ、遺伝子検査（MD）の世界規模、市場動向、市場環境、技術別（原位置ハイブリッド形成法、チップ・マイクロアレイ、質量分析法、DNA塩基配列決定法、ポリメラーゼ連鎖反応（PCR）法、細胞遺伝学、遺伝子発見、分子イメージング）分析、用途別（感染症、腫瘍学、薬理ゲノミクス、微生物学、遺伝性疾患スクリーニング、ヒト白血球型抗体タイピング、血液検査）分析、製品別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・遺伝子検査（MD）の世界市場インサイト ・遺伝子検査（MD）の世界市場環境 ・遺伝子検査（MD）の世界市場動向 ・遺伝子検査（MD）の世界市場規模 ・遺伝子検査（MD）の世界市場規模：技術別（原位置ハイブリッド形成法、チップ・マイクロアレイ、質量分析法、DNA塩基配列決定法、ポリメラーゼ連鎖反応（PCR）法、細胞遺伝学、遺伝子発見、分子イメージング） ・遺伝子検査（MD）の世界市場規模：用途別（感染症、腫瘍学、薬理ゲノミクス、微生物学、遺伝性疾患スクリーニング、ヒト白血球型抗体タイピング、血液検査） ・遺伝子検査（MD）の世界市場規模：製品別 ・遺伝子検査（MD）の世界市場：地域別市場規模・分析 ・遺伝子検査（MD）の北米市場規模・予測 ・遺伝子検査（MD）のアメリカ市場規模・予測 ・遺伝子検査（MD）のヨーロッパ市場規模・予測 ・遺伝子検査（MD）のアジア市場規模・予測 ・遺伝子検査（MD）の日本市場規模・予測 ・遺伝子検査（MD）の中国市場規模・予測 ・遺伝子検査（MD）のインド市場規模・予測 ・遺伝子検査（MD）の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global molecular diagnostics market has been estimated at around USD 7000 million in 2017. The market is expected to register a CAGR of approximately 9% during the forecast period, 2018 to 2023. North America accounted for the largest market, followed by Europe, in the molecular diagnostics market. Asia-Pacific was estimated to register approximately 15% CAGR through the forecast period, 2018-2023.
Point-of-Care Diagnostics Demand
Point-of-care testing is an emerging field in diagnostics. This generalized term encompasses tests that are portable and provide rapid results. The genetic material of an infectious agent used for detection is one of the fastest-growing point-of-care test types. Near-patient and POC tests, currently, exist for a number of pathogens, such as influenza, tuberculosis (TB), and other respiratory viruses, such as Chlamydia, gonorrhea, and group A Streptococcus (GAS). These include antigen tests (most commonly lateral-flow immunochromatographic membrane-based assays and nucleic acid tests. The POC tests are widely accepted because many tests are portable, fast, fairly simple to use, and inexpensive. Along with other factors, such as large outbreaks of bacterial and viral epidemics in the world, the rapidly evolving technology is driving the molecular diagnostics market.
Budget Limit
The end users of the market include, academic and research laboratories Fluctuation in the R&D budget can adversely affect the market growth; R&D funding fluctuates by the change in spending priorities and institutional budget. There is significant uncertainty concerning government and academic research funding worldwide, as governments in the United States and European countries, in particular, focus on reducing fiscal deficits, while confronting uncertain economic growth. Funding for life science research in some emerging countries is declining. Government funding for R&D depends on the political process, which is inherently fluid and unpredictable. Focus on programs, like defense or general efforts to minimize budget deficits can be a high priority of the government. Hence, factors, like limited budgets for R&D and economic slowdown, are restraining the growth of the market, along with other factors, such as the need for high-complexity testing centers, which are also limiting the growth of the market.
North America to Dominate the Market Growth
North America accounted for the largest market, accounting for around 44% of the global market share. The availability of robust healthcare infrastructure in North America has propelled the demand for molecular diagnostics. Along with North America, Europe is also the leading region in the global molecular diagnostics market. Asia-Pacific is fastest-growing region for molecular diagnostics and portrays huge potential for growth in the future, due to increasing government initiatives, corporate investment to standardize biopharmaceutical and healthcare industries in this region. and are projected as the fastest growing markets during the forecast period.
Key Developments in the Market
• December 2017: Saudi Arabia announced the exemption of certain medications and medical equipment from the 5% VAT, which is scheduled to be implemented from January of 2018. Saudi Arabia is imposing VAT in coordination with other governments in the Gulf Cooperation Council as they seek new sources of revenue in a bid to close budget deficits caused by low oil prices.
• October 2017: Abbott completed acquisition of Alere Inc. It is a global manufacturer of rapid point-of-care diagnostic tests.
• July 2017: Agilent Technologies had acquired molecular and sample barcoding patent portfolios of Population Genetics Technologies.
Major Players: ROCHE DIAGNOSTICS, ILLUMINA INC., HOLOGIC CORPORATION, AGILENT TECHNOLOGIES/DAKO, QIAGEN, MYRIAD GENETICS, ABBOTT LABORATORIES, CEPHEID INC., GENOMIC HEALTH INC., GRIFOLS SA amongst others.
Reasons to Purchase this Report
• Current and future molecular diagnostics market outlook in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis.
• The segment that is expected to dominate the market.
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product & Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Large Outbreaks of Bacterial and Viral Epidemics in the World
6.1.2 Increasing Demand for Point Of Care Diagnostics
6.1.3 Pharmacogenomics
6.1.4 Rapidly Evolving Technologies
6.2 Market Restraints
6.2.1 Economic Turndown
6.2.2 Need for High Complexity Testing Centers
6.2.3 Limited Budget
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation-By Technology
7.1.1 In-Situ Hybridization
7.1.1.1 ISH
7.1.1.2 FISH
7.1.2 Chips and Microarrays
7.1.3 Mass Spectroscopy
7.1.4 DNA Sequencing
7.1.4.1 Capillary Electrophoresis (CE)
7.1.4.2 Next Generation Sequencing (NGS)
7.1.5 Polymerase Chain Reaction (PCR)- Based Methods
7.1.5.1 Cold-PCR
7.1.5.2 Digital-PCR
7.1.5.3 Directlinear Analysis
7.1.5.4 Quantitative Fluorescent PCR
7.1.5.5 Real-Time PCR
7.1.5.6 Reverse Transcriptase PCR
7.1.6 Cytogenetics
7.1.7 Gene Expression- Based Studies
7.1.8 Molecular Imaging
7.1.8.1 Optical Imaging
7.1.8.2 FDG-PET
7.2 By Application
7.2.1 Infectious Disease
7.2.2 Oncology
7.2.3 Pharmacogenomics
7.2.4 Microbiology
7.2.5 Genetic Disease Screening
7.2.6 Human Leukocyte Antigen Typing
7.2.7 Blood Screening
7.3 By Product
7.3.1 Instruments
7.3.2 Reagents
7.3.3 Software and Services
7.4 By End-Users
7.4.1 Hospitals
7.4.2 Academics
7.4.3 Research Laboratories
7.5 Segmentation-By Geography
7.5.1 North America
7.5.1.1 US
7.5.1.2 Canada
7.5.1.3 Mexico
7.5.2 Europe
7.5.2.1 France
7.5.2.2 Germany
7.5.2.3 UK
7.5.2.4 Italy
7.5.2.5 Spain
7.5.2.6 Rest of Europe (RoE)
7.5.3 Asia-Pacific
7.5.3.1 China
7.5.3.2 Japan
7.5.3.3 India
7.5.3.4 Australia & New Zealand
7.5.3.5 South Korea
7.5.3.6 Rest of Asia-Pacific
7.5.4 Middle East & Africa
7.5.4.1 GCC
7.5.4.2 South Africa
7.5.4.3 Rest of the Middle East & Africa
7.5.5 South America
7.5.5.1 Brazil
7.5.5.2 Argentina
7.5.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations & Partnerships
8.3 New Products Launches
9. Key Players
9.1 Roche Diagnostics
9.2 Illumina, Inc.
9.3 Hologic Corporation
9.4 Agilent Technologies/Dako
9.5 Qiagen
9.6 Myriad Genetics
9.7 Bd (Becton, Dickinson And Company)
9.8 Abbott Laboratories
9.9 Cepheid Inc.
9.10 Genomic Health Inc.
9.11 Others
10. Future of the Market